Navigation Links
Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer

Cryoablation Offers Second Chance for Patients Whose Cancer Returns after


IRVINE, Calif., June 6 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation, announced today that a group of the nation's leading academic institutions are collaborating on an 800-patient, multi-center, prospective study of the effectiveness of cryoablation on men whose prostate cancer has recurred after radiation therapy. The study, called SCORE (Salvage Cryotherapy Registry Evaluation) is being led by E. David Crawford, M.D., and Al Barqawi, M.D., both of the University of Colorado Cancer Center, and physicians from up to 25 leading medical institutions, including M.D. Anderson Cancer Center, Loma Linda University, Washington University, the University of Tennessee and Maimonides Medical Center, are expected to participate.

Statistics show that 25 to 30 percent of men who undergo brachytherapy or external beam radiation treatments as a primary therapy for prostate cancer suffer a recurrence in three to five years. For these men, follow-up radiation therapy (also known as salvage radiation) and follow-up surgery (also known as salvage prostatectomy) can be effective but they invite additional risk and complications, according to Dr. Crawford.

"A substantial population of prostate cancer patients has the cancer return after radiation," Dr. Crawford said. "In my practice, salvage cryoablation has replaced salvage prostatectomy because it is less invasive and has minimal morbidity. Physicians have been recommending cryoablation in this circumstance for years and this study should provide us the data we need to evaluate and confirm the treatment as an important and proven option for these men."

"We believe that this study will demonstrate what more and more urologists already know -- that cryoablation can give these patients a great second chance," said Craig T. Davenport, Endocare Chairman, President and Chief Executive Officer. "This should be very welcome news to the thousands of patients each year who have undergone radiation therapy only to see their cancer come back. These so-called 'salvage' patients have very few options other than hormone therapy. The study will be used to determine the best methods for diagnosis, treatment and follow-up of these salvage patients. We look forward to following this study because the most modern and advanced cryoablation technology available will be used. While previous salvage studies show good results, we expect these outcomes to be even better."

Cryoablation is a procedure during which the physician freezes and destroys the cancerous tumors in the prostate gland. Endocare developed and manufactures the industry's leading cryoablation device, the Endocare Cryocare(R) System. Patients who undergo cryoablation often are released within 24 hours of the procedure and are able to return to normal activity within a few days.

The SCORE Study is the largest prospective trial ever undertaken in cryoablation. Investigators will collect uniform, HIPAA compliant, anonymous patient data for collaborative analysis and publication. Data components, which are based on an Institutional Review Board (IRB) approved protocol, include diagnostics, cryoablation procedure, clinical follow-up and complications.

A national patient educational and awareness campaign is underway to find patients with recurrent prostate cancer following radiation. A number of additional academic and community centers are in the process of joining the study. Additional information can be found at, a website that has been created to educate prospective patients about the study. Also, interested parties can call 1-877-722-2796 to speak to a patient advocate about SCORE or salvage cryotherapy.

About Endocare

Endocare, Inc. -- -- is an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. These forward-looking statements, include, but are not limited to, statements regarding expected participation in, and expected results of, the study described in this press release. Actual results may differ materially from any forward-looking statements due to such risks and uncertainties. These risks and uncertainties include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
5. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
8. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
9. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
10. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for ... of 217 pages published in November 2015 to ... online business intelligence library at . ... of the fastest growing global economies with a ...
(Date:11/24/2015)... LONDON , November 24, 2015 ... platform for scientists - since it was launched just six ... collaboration, reference management and authoring platform for scientists - since ... One million references have been loaded on to F1000Workspace ... for scientists - since it was launched just six months ...
(Date:11/24/2015)... , November 24, 2015 st  Scientific ... North America (RSNA) taking place in Chicago ... Booth 1122, Hall A. --> st  Scientific Assembly and ... (RSNA) taking place in Chicago ... Hall A. --> Molecular Dynamics will present its revolutionary ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Since its ... comprehensive solutions involving adult stem cell therapies to patients with chronic degenerative medical ... name as a Registered Trademark (RTM). , Organizations are required to hold a ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted ... to many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ ... of time the doctor uses other traditional cutting tools, such as the scalpel and ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... 2015 , ... Cancer patients, survivors, caregivers, family members and ... taping of the next CURE Connections® video series on Saturday, Dec. ... at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE Connections, ...
Breaking Medicine News(10 mins):